ARTELO BIOSCIENCES, INC. (ARTL) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
10/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseARTL / S&P -85.22% / 15.20% |
LoseARTL / S&P ARTL unavailable / 15.00% |
LoseARTL / S&P -76.90% / 50.40% |
| 2026-Q11/3 |
WinARTL / S&P 107.10% / -4.33% |
LoseARTL / S&P ARTL unavailable / 11.30% |
LoseARTL / S&P -5.04% / 27.70% |
| 2025-Q41/3 |
LoseARTL / S&P -73.42% / 2.65% |
LoseARTL / S&P ARTL unavailable / 9.00% |
WinARTL / S&P 131.76% / 13.40% |
| 2025-Q31/3 |
LoseARTL / S&P -65.41% / 8.12% |
LoseARTL / S&P ARTL unavailable / 4.61% |
WinARTL / S&P 381.53% / 13.45% |
| 2025-Q22/3 |
WinARTL / S&P 152.76% / 10.94% |
LoseARTL / S&P ARTL unavailable / 4.83% |
WinARTL / S&P 441.15% / 10.63% |
| 2025-Q10/3 |
LoseARTL / S&P -17.45% / -4.27% |
LoseARTL / S&P ARTL unavailable / 4.98% |
LoseARTL / S&P ARTL unavailable / 10.57% |
| 2024-Q40/3 |
LoseARTL / S&P -5.36% / 2.41% |
LoseARTL / S&P ARTL unavailable / 5.25% |
LoseARTL / S&P ARTL unavailable / 6.15% |
| 2024-Q30/3 |
LoseARTL / S&P -16.42% / 5.89% |
LoseARTL / S&P ARTL unavailable / 5.89% |
LoseARTL / S&P ARTL unavailable / 6.11% |
| 2024-Q20/3 |
LoseARTL / S&P -9.46% / 4.28% |
LoseARTL / S&P ARTL unavailable / 5.38% |
LoseARTL / S&P ARTL unavailable / 5.12% |
| 2024-Q10/3 |
LoseARTL / S&P 5.71% / 10.56% |
LoseARTL / S&P ARTL unavailable / 5.71% |
LoseARTL / S&P ARTL unavailable / 5.59% |
| 2023-Q40/3 |
LoseARTL / S&P -4.11% / 11.69% |
LoseARTL / S&P ARTL unavailable / 6.81% |
LoseARTL / S&P ARTL unavailable / 7.78% |
| 2023-Q30/3 |
LoseARTL / S&P -26.63% / -3.27% |
LoseARTL / S&P ARTL unavailable / 7.52% |
LoseARTL / S&P ARTL unavailable / -5.03% |
| 2023-Q20/3 |
LoseARTL / S&P -14.22% / 8.74% |
LoseARTL / S&P ARTL unavailable / 9.50% |
LoseARTL / S&P ARTL unavailable / -8.57% |
| 2023-Q10/3 |
LoseARTL / S&P -19.72% / 7.50% |
LoseARTL / S&P ARTL unavailable / 10.77% |
LoseARTL / S&P ARTL unavailable / -15.69% |
| 2022-Q40/3 |
LoseARTL / S&P -16.23% / 7.56% |
LoseARTL / S&P ARTL unavailable / 11.88% |
LoseARTL / S&P ARTL unavailable / -17.99% |
| 2022-Q30/3 |
LoseARTL / S&P -27.44% / -4.88% |
LoseARTL / S&P ARTL unavailable / 13.47% |
LoseARTL / S&P ARTL unavailable / -1.41% |
| 2022-Q20/3 |
LoseARTL / S&P -29.56% / -16.10% |
LoseARTL / S&P ARTL unavailable / 13.71% |
LoseARTL / S&P ARTL unavailable / 11.04% |
| 2022-Q10/3 |
LoseARTL / S&P -13.29% / -4.60% |
LoseARTL / S&P ARTL unavailable / 15.97% |
LoseARTL / S&P ARTL unavailable / 42.23% |
| 2021-Q40/3 |
LoseARTL / S&P -34.39% / 11.03% |
LoseARTL / S&P ARTL unavailable / 15.00% |
LoseARTL / S&P ARTL unavailable / 96.40% |
| 2021-Q30/3 |
LoseARTL / S&P -33.53% / 0.58% |
LoseARTL / S&P ARTL unavailable / 10.77% |
LoseARTL / S&P ARTL unavailable / 69.42% |
| 2021-Q20/3 |
LoseARTL / S&P -26.99% / 8.55% |
LoseARTL / S&P ARTL unavailable / 6.58% |
LoseARTL / S&P ARTL unavailable / 51.81% |
| 2021-Q11/3 |
WinARTL / S&P 123.29% / 6.17% |
LoseARTL / S&P ARTL unavailable / -1.06% |
LoseARTL / S&P ARTL unavailable / 7.39% |
| 2020-Q40/3 |
LoseARTL / S&P -26.49% / 12.15% |
LoseARTL / S&P ARTL unavailable / -3.72% |
LoseARTL / S&P ARTL unavailable / -33.42% |
| 2020-Q30/3 |
LoseARTL / S&P -17.93% / 8.93% |
LoseARTL / S&P ARTL unavailable / -2.04% |
LoseARTL / S&P ARTL unavailable / -27.10% |
| 2020-Q21/3 |
WinARTL / S&P 26.04% / 20.54% |
LoseARTL / S&P ARTL unavailable / -0.46% |
LoseARTL / S&P ARTL unavailable / -27.11% |
| 2020-Q11/3 |
LoseARTL / S&P -64.44% / -19.60% |
LoseARTL / S&P ARTL unavailable / 3.47% |
WinARTL / S&P -10.50% / -14.75% |
| 2019-Q42/3 |
WinARTL / S&P 24.94% / 9.07% |
LoseARTL / S&P ARTL unavailable / 5.36% |
WinARTL / S&P 9.46% / 2.99% |
| 2019-Q30/3 |
LoseARTL / S&P -53.02% / 1.70% |
LoseARTL / S&P ARTL unavailable / 5.02% |
LoseARTL / S&P ARTL unavailable / 0.21% |
| 2019-Q20/3 |
LoseARTL / S&P ARTL unavailable / 4.30% |
LoseARTL / S&P ARTL unavailable / 6.64% |
LoseARTL / S&P ARTL unavailable / 8.65% |
| 2019-Q10/3 |
LoseARTL / S&P ARTL unavailable / 13.65% |
LoseARTL / S&P ARTL unavailable / 8.12% |
LoseARTL / S&P ARTL unavailable / 14.29% |
| 2018-Q40/3 |
LoseARTL / S&P ARTL unavailable / -13.52% |
LoseARTL / S&P ARTL unavailable / 9.05% |
LoseARTL / S&P ARTL unavailable / 18.23% |
| 2018-Q30/3 |
LoseARTL / S&P ARTL unavailable / 7.71% |
LoseARTL / S&P ARTL unavailable / 10.21% |
LoseARTL / S&P ARTL unavailable / 19.06% |
| 2018-Q20/3 |
LoseARTL / S&P ARTL unavailable / 3.43% |
LoseARTL / S&P ARTL unavailable / 9.03% |
LoseARTL / S&P ARTL unavailable / 14.46% |
| 2018-Q10/3 |
LoseARTL / S&P ARTL unavailable / -0.76% |
LoseARTL / S&P ARTL unavailable / 7.68% |
LoseARTL / S&P ARTL unavailable / 12.46% |
| 2017-Q40/3 |
LoseARTL / S&P ARTL unavailable / 6.64% |
LoseARTL / S&P ARTL unavailable / 7.03% |
LoseARTL / S&P ARTL unavailable / 13.82% |
| 2017-Q30/3 |
LoseARTL / S&P ARTL unavailable / 4.48% |
LoseARTL / S&P ARTL unavailable / 5.68% |
LoseARTL / S&P ARTL unavailable / 17.57% |
| 2017-Q20/3 |
LoseARTL / S&P ARTL unavailable / 3.09% |
LoseARTL / S&P ARTL unavailable / 4.83% |
LoseARTL / S&P ARTL unavailable / 17.74% |
| 2017-Q10/3 |
LoseARTL / S&P ARTL unavailable / 6.07% |
LoseARTL / S&P ARTL unavailable / 3.67% |
LoseARTL / S&P ARTL unavailable / 13.32% |
| 2016-Q40/3 |
LoseARTL / S&P ARTL unavailable / 3.82% |
LoseARTL / S&P ARTL unavailable / 2.09% |
LoseARTL / S&P ARTL unavailable / 7.05% |
| 2016-Q30/3 |
LoseARTL / S&P ARTL unavailable / 3.85% |
LoseARTL / S&P ARTL unavailable / 0.20% |
LoseARTL / S&P ARTL unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ARTL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.62% | 20.78% |
| Annualized return | -97.62% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ARTL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.74% | 83.14% |
| Annualized return | -69.68% | 12.86% |
10Y · 2019-06-21 to 2026-08-27
| Metric | ARTL total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.95% | 319.30% |
| Annualized return | -53.00% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B |